Literature DB >> 26525799

Acquired Flucytosine Resistance during Combination Therapy with Caspofungin and Flucytosine for Candida glabrata Cystitis.

Caroline Charlier1, Carine El Sissy2, Sophie Bachelier-Bassi3, Anne Scemla4, Gilles Quesne2, Emilie Sitterlé2, Christophe Legendre4, Olivier Lortholary5, Marie-Elisabeth Bougnoux6.   

Abstract

Treatment of Candida glabrata cystitis remains a therapeutic challenge, and an antifungal combination using flucytosine is one option. We describe two patients with refractory C. glabrata cystitis who failed flucytosine combined with caspofungin with early-acquired high-level resistance to flucytosine due to nonsense mutations in the FUR1 gene. Rapidly acquired flucytosine resistance with microbiological failure should discourage combination of caspofungin and flucytosine during urinary candidiasis.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26525799      PMCID： PMC4704181          DOI： 10.1128/AAC.02265-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Candida urinary tract infections--treatment.

Authors:  John F Fisher; Jack D Sobel; Carol A Kauffman; Cheryl A Newman
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

2.  Caspofungin in the treatment of symptomatic candiduria.

Authors:  Jack D Sobel; Susan K Bradshaw; C Joy Lipka; Nicholas A Kartsonis
Journal:  Clin Infect Dis       Date:  2007-01-22       Impact factor: 9.079

3.  C. albicans resistance to 5-fluorocytosine.

Authors:  R L Logan; M J Goldberg
Journal:  Br Med J       Date:  1972-08-26

4.  Development of resistance to 5-fluorocytosine in Candida parapsilosis during therapy.

Authors:  P D Hoeprich; J L Ingraham; E Kleker; M J Winship
Journal:  J Infect Dis       Date:  1974-08       Impact factor: 5.226

5.  Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts.

Authors:  Susan J Howard; Joanne Livermore; Andrew Sharp; Joanne Goodwin; Lea Gregson; A Alastruey-Izquierdo; D S Perlin; Peter A Warn; William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2011-08-01       Impact factor: 5.191

6.  Mutational analysis of flucytosine resistance in Candida glabrata.

Authors:  Thomas D Edlind; Santosh K Katiyar
Journal:  Antimicrob Agents Chemother       Date:  2010-09-07       Impact factor: 5.191

Review 7.  Amphotericin B and flucytosine in the treatment of candidal cystitis.

Authors:  J A Paladino; R E Crass
Journal:  Clin Pharm       Date:  1982 Jul-Aug

8.  A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis.

Authors:  Robert F Betts; Marcio Nucci; Deepak Talwar; Marcelo Gareca; Flavio Queiroz-Telles; Roger J Bedimo; Raoul Herbrecht; Guillermo Ruiz-Palacios; Jo-Anne H Young; John W Baddley; Kim M Strohmaier; Kimberly A Tucker; Arlene F Taylor; Nicholas A Kartsonis
Journal:  Clin Infect Dis       Date:  2009-06-15       Impact factor: 9.079

9.  Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient.

Authors:  Florence Chapeland-Leclerc; Christophe Hennequin; Nicolas Papon; Thierry Noël; Aurélie Girard; Gérard Socié; Patricia Ribaud; Claire Lacroix
Journal:  Antimicrob Agents Chemother       Date:  2009-12-28       Impact factor: 5.191

10.  The Candida genome database incorporates multiple Candida species: multispecies search and analysis tools with curated gene and protein information for Candida albicans and Candida glabrata.

Authors:  Diane O Inglis; Martha B Arnaud; Jonathan Binkley; Prachi Shah; Marek S Skrzypek; Farrell Wymore; Gail Binkley; Stuart R Miyasato; Matt Simison; Gavin Sherlock
Journal:  Nucleic Acids Res       Date:  2011-11-07       Impact factor: 16.971
View more
  6 in total

Review 1.  Targeting efflux pumps to overcome antifungal drug resistance.

Authors:  Ann R Holmes; Tony S Cardno; J Jacob Strouse; Irena Ivnitski-Steele; Mikhail V Keniya; Kurt Lackovic; Brian C Monk; Larry A Sklar; Richard D Cannon
Journal:  Future Med Chem       Date:  2016-07-27       Impact factor: 3.808

2.  Candida auris Pan-Drug-Resistant to Four Classes of Antifungal Agents.

Authors:  Samantha E Jacobs; Jonathan L Jacobs; Emily K Dennis; Sarah Taimur; Meenakshi Rana; Dhruv Patel; Melissa Gitman; Gopi Patel; Sarah Schaefer; Kishore Iyer; Jang Moon; Victoria Adams; Polina Lerner; Thomas J Walsh; YanChun Zhu; Mohammed Rokebul Anower; Mayuri M Vaidya; Sudha Chaturvedi; Vishnu Chaturvedi
Journal:  Antimicrob Agents Chemother       Date:  2022-06-30       Impact factor: 5.938

Review 3.  Mechanisms of Candida Resistance to Antimycotics and Promising Ways to Overcome It: The Role of Probiotics.

Authors:  Konstantin A Demin; Aleksandr G Refeld; Anna A Bogdanova; Evgenya V Prazdnova; Igor V Popov; Olga Yu Kutsevalova; Alexey M Ermakov; Anzhelica B Bren; Dmitry V Rudoy; Vladimir A Chistyakov; Richard Weeks; Michael L Chikindas
Journal:  Probiotics Antimicrob Proteins       Date:  2021-03-18       Impact factor: 4.609

Review 4.  Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens.

Authors:  Ewa Ksiezopolska; Toni Gabaldón
Journal:  Genes (Basel)       Date:  2018-09-19       Impact factor: 4.096

Review 5.  Candida auris Urinary Tract Infections and Possible Treatment.

Authors:  Nicole Griffith; Larry Danziger
Journal:  Antibiotics (Basel)       Date:  2020-12-12

6.  Species distribution and antifungal susceptibility patterns of Candida isolates from a public tertiary teaching hospital in the Eastern Cape Province, South Africa.

Authors:  P Mnge; B I Okeleye; S D Vasaikar; T Apalata
Journal:  Braz J Med Biol Res       Date:  2017-05-15       Impact factor: 2.590
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.